Siemens, Shareholders

Siemens Shareholders Set for Healthineers Payout as Growth Test Looms

Published on 11/21/2026 at 13:51 | Editorial boerse-global.de
Siemens plans to hand 34.1% of Healthineers to shareholders as Deutsche Bank lifts its target to €275, but order conversion and profit growth remain key.
Siemens, Shareholders, Set, Healthineers, Payout, Growth, Test, Looms, Bank Illustration mit AI erstellt.

Siemens has confirmed the mechanics of its planned Healthineers separation, announcing on 12 November that it intends to hand 34.1 percent of its stake in the medical-technology unit directly to its own shareholders. Under the proposed structure, investors would receive one Siemens Healthineers share for every two Siemens shares they hold.

The disclosure lands at a delicate moment for the Munich conglomerate's equity story. Siemens stock closed at €250.00 on Thursday after shedding 5.7 percent, caught in a broad global selloff that Reuters linked to persistent doubts about the artificial intelligence sector. Deutsche Bank Research, in a note published yesterday, lifted its price target on the shares from €270 to €275 while keeping a "Hold" rating. Analyst Gael de-Bray recalibrated his valuation model to account for the spin-off — a technical adjustment that shifts how the stock is valued but says nothing about whether the industrial business will hit its own targets.

Two Separate Questions for Investors

That distinction matters. The Healthineers transfer redraws the map for valuation purposes. Whether Siemens delivers on growth is a question that can only be settled by the order book and the income statement.

Management is guiding for comparable revenue growth of 9 to 11 percent in fiscal 2027. The bar is set above the prior year: in fiscal 2026, comparable revenue rose 8 percent to €83.4 billion. Even the bottom of the 2027 range therefore assumes an acceleration.

Should investors sell immediately? Or is it worth buying Siemens?

Orders offer one clue as to whether that step-up is achievable. Comparable orders reached €108.2 billion across fiscal 2026, and the final quarter alone brought in €34.8 billion — a record and a 58 percent jump year on year. Crucially, revenue was already moving in the same direction, climbing 11 percent to €23.7 billion in the quarter. Siemens left the fiscal year with both a fuller pipeline and a growing top line.

Where the Risk Sits

The gap between bookings and billing is the pressure point. Orders in the closing quarter outran revenue by a wide margin, and if conversion slows in the current year, a further batch of record contracts would carry little weight. Siemens would then need to cram more of its growth into the back half of the fiscal year.

Profitability deserves equal scrutiny. The Industrial Business lifted its quarterly profit 22 percent to €3.9 billion, and free cash flow for the group set a record for the year. For fiscal 2027, Siemens is targeting earnings per share before purchase price allocation effects of €10.20 to €10.80. Revenue that climbs without a matching advance in industrial profit would flag trouble for that guidance — and a higher analyst target built on the Healthineers separation would offer no protection.

The board has proposed a dividend of €5.50 per share for the year just ended.

The First Real Check

Investors will get their first concrete read on the pace of conversion when comparable revenue growth for the opening quarter arrives. If that figure already supports the full-year corridor, the bullish case holds. If it lags despite the swollen backlog, the explanation will matter as much as the number: a timing shift inside the fiscal year carries different implications for guidance than a shortfall Siemens cannot make up in subsequent quarters.

Ad

Siemens Stock: New Analysis - 21 November

Fresh Siemens information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Siemens analysis...

Disclaimer...
en | DE0007236101 | SIEMENS | boerse | 70542649 |